Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2013

View Archived Issues

Leica Biosystems and Synthon Biopharmaceuticals enter partnership

Gedeon Richter divulges novel H3 receptor ligands

Pfizer prepares new BRD4 inhibitors

The novel mechanistic properties of AF-710B result in excellent cognitive enhancement in vivo

Tyrosine-protein kinase BTK as promising biomarker for lymphomas

Safety of ZN-2007 evaluated in rats and monkeys

MiStent demonstrates significant neointimal suppression in human coronary lesions

Bexarotene restores memory deficit in transgenic models of Alzheimer's disease

Sinovac's EV71 vaccine shows efficacy against HFMD in phase III study

Nanosphere gains clearance in E.U. for Gram-Negative Blood Culture test

The role of CD28 in controlling Treg function and survival

Novel Chinese yam-derived protein patented for menopause and osteoporosis

A novel selective NMDA receptor antagonist shows promising results in vivo

ThromboGenics discloses potential new eye disorder treatments

Genfit discovers novel ligands for the treatment of autoimmune diseases

FDA sets PDUFA date for QRxPharma's resubmitted MoxDuo NDA

Oxford Gene Technology obtains license to prostate cancer biomarker

PRASFIT-Elective study results announced by Daiichi Sankyo

G-202 obtains FDA orphan drug designation

Novel cancer peptide vaccines prepared in Japan

ARC-520 reduces circulating HBV DNA in chimpanzee with chronic hepatitis B

Isofol Medical completes first part of preclinical safety program for Modufolin

Ligand signs global license agreement with Spectrum for Captisol-enabled melphalan

Vanda withdraws MAA for schizophrenia treatment candidate

FDA reviewing possible safety risk associated with incretin mimetic drugs for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...